Physician profile
Jane Semel
NPI 1083608004
$8,143.31
in general payments reported to CMS, 2019-2025
32 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $1,076 · 2021: $506 · 2022: $893 · 2023: $992 · 2024: $1,856 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,018 · Long Term Medical Supply Or Device Loan: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,018.48 |
| Long Term Medical Supply Or Device Loan | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $932.10 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $761.61 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $758.44 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $667.61 | 2022-2025 | Miebo, Xiidra, Prolensa |
| Stryker Corporation | $547.10 | 2024-2025 | Alphavent, Salvation |
| Alcon Vision LLC | $508.68 | 2019-2025 | Rocklatan, Eysuvis, Tryptyr |
| Ocular Therapeutix, INC. | $440.33 | 2022-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $434.19 | 2019-2021 | |
| Abbvie INC. | $419.88 | 2022-2024 | Botox, Xen Glaucoma Treatment System, Durysta |
| Mallinckrodt Hospital Products INC. | $373.15 | 2020-2024 | Acthar |
| Rxsight INC | $373.09 | 2023-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Harrow Eye, LLC | $275.54 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $249.37 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $203.16 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $170.64 | 2019-2024 | Acuvue |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $144.40 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $116.13 | 2019 | |
| Biotissue Holdings INC. | $110.49 | 2022 | |
| Thea Pharma INC. | $84.37 | 2022-2024 | Iyuzeh |
| Horizon Therapeutics Plc | $70.36 | 2021-2022 | |
| Dompe US, INC. | $66.77 | 2024 | Oxervate |
| Coopervision INC. | $62.82 | 2023 | Myday Contact Lens, Misight Contact Lens, Onefit Contact Lens |
| Aerie Pharmaceuticals, INC. | $56.32 | 2019-2020 | |
| Cardinal Health 108 LLC | $54.03 | 2022 | |
| Shire North American Group INC | $44.52 | 2019 | |
| Galderma Laboratories, L.P. | $44.26 | 2019 | |
| Glaukos Corporation | $39.66 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $36.87 | 2022-2023 | Flarex |
| Johnson & Johnson Surgical Vision, INC. | $28.49 | 2021-2022 | |
| Merz North America, INC. | $26.01 | 2019 | |
| Amgen INC. | $24.74 | 2024 | Tepezza |
| Alimera Sciences, INC. | $18.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Semel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.